Drug Delivery

Three patents issued for adeno-associated virus vector technology

Published in Gene Therapy Weekly, June 13th, 2002

Avigen, Inc., (AVGN) announced it has received three new patents, strengthening its expansive intellectual property portfolio in adeno-associated virus (AAV) vector technology. Two of the patents cover advances in the delivery of AAV. The third covers the cells used in Avigen's AAV manufacturing process, which result in significantly enhanced yields.

United States Patent No. 6,325,998 covers the use of recombinant AAV, free of both wild-type AAV and infectious helper virus, to deliver any therapeutic gene to muscle cells, including skeletal, smooth and cardiac muscle. United States Patent No. 6,335,011 covers methods for delivering genes via AAV to muscle tissue to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-06-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry